Comparison of Real-World Safety and Effectiveness of Mepolizumab and Benralizumab in the Management of Severe Asthma: A Systematic Review


Bhavanasai S1, Vullengala N1, Yarramsetti P1, Jan R1, Kaur G1, Udhayasri R1, Sodhi B1, Gomes A1, Dang A2, Dang D1, Vallish BN1
1MarksMan Healthcare Communications, Hyderabad, Telangana, India, 2MarksMan Healthcare Communications, Hyderabad, AP, India

OBJECTIVES: To compare the clinical (safety, effectiveness) and humanistic (QoL and other PROs) outcomes associated with mepolizumab and benralizumab in the management of severe asthma in real-world settings

METHODS: We searched PubMed for relevant records on 9th November 2022, using appropriate search strategies. Publication details, demographics, intervention, comparator, effectiveness, safety and humanistic outcomes were extracted from eligible records.

RESULTS: Of 920 records screened, 7 studies (1 prospective and 6 retrospective observational studies) with a total of 867 unique patients with different forms of severe asthma (females: 489, males: 378) were included. Mean age of participants ranged from 46±13.9 years to 57.2±12.1 years. Dosing of mepolizumab and benralizumab was as per USFDA-recommended dosage in 3 and 2 studies respectively. Efficacy, safety, and PROs were reported in 7, 3, and 2 of the included studies, but there was a lack of uniformity in the metrics used to assess effectiveness outcomes in included studies. Both mepolizumab and benralizumab were associated with reduction in asthma exacerbations, improvements in Forced Expiratory Volume in 1 Second (FEV1), Forced Vital Capacity (FVC), and FEV1/FVC ratio, and improvements in quality of life (as evidenced by ACQ and AQLQ scores); the differences between the outcomes of the two drugs was not statistically significant. No new safety signals were detected.

CONCLUSIONS: Both mepolizumab and benralizumab are safe and effective in severe asthma patients treated in real-world settings. There were minimal differences in the effectiveness, safety and humanistic outcomes of mepolizumab and benralizumab in severe asthma.

Conference/Value in Health Info

2023-11, ISPOR Europe 2023, Copenhagen, Denmark

Value in Health, Volume 26, Issue 11, S2 (December 2023)




Clinical Outcomes, Study Approaches

Topic Subcategory

Clinical Outcomes Assessment, Comparative Effectiveness or Efficacy, Literature Review & Synthesis


Biologics & Biosimilars, Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now